Gilead Sciences Inc(GILD)

67.40

Change: 0 (0)

As of Wed 10/06/2021 03:01 AM

% Of Value

Growth

Value Per Share

:

:

:

145.86

10.60

46.2100 (as of 19/07/2019)

NO DATA TO DISPLAY
NO DATA TO DISPLAY
NO DATA TO DISPLAY
NO DATA TO DISPLAY

Fundamentals Data

Open 67.80 Dividend 1358
Close Price 67.40 DivYield 2.42 %
High 67.83 Growth 0.0
Low 66.66 Growth% 10.60
P/e 15.28 Volume 5.7 M
P/b 11.39 Market Capital 84.6 B
Highest High 85.47 Lowest Low 64.12
50 Days Moving Average 65.95 (as of 03/07/2019) 50 Days Moving Average Percentage -5.904 (as of 03/07/2019
Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Charts for balance Sheet:

Balance Sheet Table: last 5 years

Note: Numbers are estimated, Exact figures can be found in Annual Reports
Type Year1 / 2017 Year2 / 2018 Year3 / 2019 Year4 / 2020 Current Year / 2021
Revenue 26.1 B 22.1 B 22.4 B 24.6 B 27.3 B
Cap Spending -590.0 M -924.0 M -825.0 M -650.0 M -579.0 M
Operating Expenses 7.6 B 9.0 B 13.4 B 16.0 B 10.7 B
Operating Cash Flow 14.1 B 8.2 B 4.2 B 4.0 B 9.9 B
Free Cash Flow 11.3 B 7.4 B 8.3 B 7.5 B 10.8 B
Free Cash Flow Per Share 8.652 5.76 6.55 5.981 8.603
Total liabilities 33.5 B 27.3 B 24.5 B 31.4 B 26.6 B
Total cash 7.5 B 17.9 B 11.6 B 5.9 B 5.3 B
ROE% 0.209 0.252 0.246 0.006 0.307
Outstanding Shares 1.3 B 1.2 B 1.2 B 1.2 B 1.2 B
P/E 22.746 15.264 16.447 641.475 12.358
P/S 4.032 3.763 3.946 3.196 2.817
Revenue USD 26.1 B 22.1 B 22.4 B 24.6 B 27.3 B

Reports for GILD

Date Author Title Action
2020-09-08 stanko Gilead Sciences equity, debt and subsidiaries view
2016-10-13 stanko gilead is the leader of hep C drugs and 14 brand names with 1/3 of market cap in debt view

Latest Searches

Stock Close Price %of value Date